参考文献/References:
[1] Cribier A,Eltchaninoff H,Bash A,et al.Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis:first human case description[J].Circulation, 2002,106(24):3006-3008.
[2] Leon MB, Smith CR,Mack M,et al.Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery[J].N Engl J Med,2010,363(17):1597-1607.
[3] Lefevre T, Kappetein AP,Wolner E,et al.One year follow-up of the multi-centre European PARTNER transcatheter heart valve study[J]. Eur Heart J, 2011,32(2):148-1457.
[4] Makkar RR, Fontana GP,Jilaihawi H,et al.Transcatheter aortic-valve replacement for inoperable severe aortic stenosis[J]. N Engl J Med,2012,366(18):1696-1704.
[5] Kapadia SR,Leon MB,Makkar RR,et al.5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis(PARTNER 1): a randomised controlled trial[J].Lancet,2015, 385(9986):2485-2491.
[6] Douglas PS, Hahn RT, Pibarot P,et al.Hemodynamic outcomes of transcatheter aortic valve replacement and medical management in severe,inoperable aortic stenosis: a longitudinal echocardiographic study of cohort B of the PARTNER trial[J].J Am Soc Echocardiogr,2015,28(2):210-217.
[7] 潘文志,周达新,葛均波.经导管心脏瓣膜治疗2014年度盘点[J].中国医学前沿杂志(电子版),2015,1(1):120-122
[8] Barbanti M, Petronio AS, Ettori F,et al.5-Year Outcomes After Transcatheter Aortic Valve Implantation With CoreValve Prosthesis[J]. JACC Cardiovasc Interv, 2015, 8(8):1084-1091.
[9] van Brabandt HF, Neyt M, Hulstaert F. Transcatheter aortic valve implantation(TAVI): risky and costly[J].BMJ,2012,345:e4710.
[10] Adams DH,Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self-expanding prosthesis[J].N Engl J Med,2014,371(10):967-968.
[11] Abdel-Wahab M, Mehilli J, Frerker C,et al.Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial[J].JAMA,2014,311(15):1503-1514.
[12] Abdel-Wahab M,Neumann FJ, Mehilli J et al.1-Year Outcomes After Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expandable Valves: Results From the CHOICE Randomized Clinical Trial[J].J Am Coll Cardiol,2015,66(7):791-800.
[13] 周达新,潘文志,管丽华,等 经导管主动脉瓣置入治疗二叶式钙化性主动脉瓣狭窄一例报道[J].中国介入心脏病学杂志, 2013,(2):127-128.
[14] McCormick LM, Gooley R, Lockwood S,et al.First reported use of the repositionable lotus valve system for a failing surgical aortic bioprosthesis[J].JACC Cardiovasc Interv,2015,8(2):e19-20.
[15] Gooley RP, Talman AH, Cameron JD,et al.Comparison of Self-Expanding and Mechanically Expanded Transcatheter Aortic Valve Prostheses[J].JACC Cardiovasc Interv,2015,8(7):962-971.
[16] Murdoch D, Shaw E,Raffel OC,et al.Next generation TAVI with the Lotus Valve System:a repositionable and fully retrievable transcatheter aortic valve prosthesis[J].Minerva Cardioangiol,2015,63(4):343-357.
[17] Wohrle J, Rodewald C, Rottbauer W. Transfemoral aortic valve implantation in pure native aortic valve insufficiency using the repositionable and retrievable lotus valve[J].Catheter Cardiovasc Interv,2015,doi:10.1002/ccd260629[Epub ahead of print].
[18] Meredith IT,Hood KL.Haratani N,et al.Boston Scientific Lotus valve[J].EuroIntervention,2012,8(Suppl Q):Q70-74.
[19] Jilaihawi H, Wu Y,Yang Y, et al.Morphological characteristics of severe aortic stenosis in China:imaging corelab observations from the first China, transcatheter aortic valve trial[J].Catheter Cardiovasc Interv,2015,85(Suppl 1):752-761.
[20] 刘庆荣,吕守良,吴永健.国产Venus A-Valve人工主动脉瓣膜的设计特点[J].中国医刊,2015, 50(1): 9-10.
[21] 管丽华,周达新,葛均波.高龄二尖瓣狭窄患者经皮二尖瓣球囊扩张术治疗的疗效分析[J]. 中国临床医学, 2012,(5):464-466.
[22] 潘文志,周达新,葛均波.经导管缘对缘二尖瓣修复术的研究进展[J].中国医学前沿杂志(电子版), 2012, 4(8):14-18.
[23] Swaans MJ, Bakker AL, Alipour A,et al.Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients[J].JACC Cardiovasc Interv,2014,7(8):875-881.
[24] 葛均波.评国内首例经导管二尖瓣修复术成功[J].中国介入心脏病学杂志, 2012,(3):121-122.
[25] 周达新, 潘文志,管丽华,等. MitraClip治疗二尖瓣反流三例中期随访报道[J]. 中国介入心脏病学杂志, 2013,(4): 240-243.
[26] Piazza N, Asgar A,Ibrahim R,et al.Transcatheter mitral and pulmonary valve therapy[J].J Am Coll Cardiol,2009,53(20):1837-1851.
[27] Siminiak T, Dankowski R,Baszko A,et al.Percutaneous direct mitral annuloplasty using the Mitralign Bident system:description of the method and a case report[J].Kardiol Pol,2013,71(12):1287-1292.
[28] Harnek J, Webb JG,Kuck KH,et al.Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation: 1-year results from the EVOLUTION phase I study(Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation)[J].JACC Cardiovasc Interv,2011,4(1):115-122.
[29] Ye J, Cheung A,Lichtenstein SV,et al.Six-month outcome of transapical transcatheter aortic valve implantation in the initial seven patients[J].Eur J Cardiothorac Surg,2007,31(1):16-21.
[30] di Marco F,Gerosa G. Percutaneous aortic valve replacement: which patients are suitable for it? A quest for a controlled use[J].J Thorac Cardiovasc Surg,2007,133(2):294-298.
[31] Mack M.Presentation at TransCatheter Therapeutics 23rd Annual Scientific Symposium[R]. San Francisco,2011,November 7-11.
[32] Sondergaard L, de Backer O, Franzen OW,et al.First-in-Human Case of Transfemoral CardiAQ Mitral Valve Implantation[J]. Circ Cardiovasc Interv, 2015,8(7): e002135.
[33] Bapat V, Buellesfeld L,Peterson MD,et al.Transcatheter mitral valve implantation(TMVI)using the Edwards FORTIS device[J].EuroIntervention,2014,10(Suppl U):U120-128.
[34] 潘文志,周达新,葛均波.经皮肺动脉瓣置入术的研究进展[J]. 中国医学前沿杂志(电子版), 2013,(6):24-28.
[35] Inc VMH, Zhou DX.Efficacy and Safety of Venus P-valve to Treat RVOT Stenosis With Pulmonary Regurgitation[R]. 2015.
[36] 周达新,潘文志,管丽华,等.经皮肺动脉瓣置入二例报道[J].中国介入心脏病学杂志, 2013,(5):332-334.
[37] Promphan W, Prachasilchai P, Siripornpitak S,et al.Percutaneous pulmonary valve implantation with the Venus P-valve: clinical experience and early results[J].Cardiol Young,2015,19:1-13.
[38] Cao QL, Kenny D,Zhou D,et al.Early clinical experience with a novel self-expanding percutaneous stent-valve in the native right ventricular outflow tract[J].Catheter Cardiovasc Interv,2014,84(7):1131-1137.
相似文献/References:
[1]闵敏,综述,邱艳霞,等.粥样硬化性肾动脉狭窄介入适应证的探讨[J].心血管病学进展,2016,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.004]
MIN Min,QIU Yanxia,JIA Nan.Indications of Endovascular Procedure for Atherosclerotic Renal Artery Stenosis[J].Advances in Cardiovascular Diseases,2016,(5):231.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.004]
[2]朱静怡,迟迪,刘向兰,等.主动脉窦瘤破裂的介入治疗进展[J].心血管病学进展,2015,(5):538.[doi:10.3969/j.issn.1004-3934.2015.05.004]
ZHU Jingyi,CHI Di,LIU Xianglan,et al.Progress in Transcatheter Interventional Treatment of Ruptured
Sinus of Valsalva Aneurysm[J].Advances in Cardiovascular Diseases,2015,(5):538.[doi:10.3969/j.issn.1004-3934.2015.05.004]
[3]徐学萍 汪汉 蔡琳.结缔组织病相关心脏瓣膜病[J].心血管病学进展,2019,(9):1267.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.021]
XU Xueping,WANG Han,CAI Lin.Connective Tissue Disease-associated Valvular Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):1267.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.021]
[4]刘古月 白文娟 唐红.实时三维经食管超声心动图对心脏瓣膜病的量化评估进展[J].心血管病学进展,2020,(10):1053.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.013]
LIU Guyue,BAI Wenjuan,TANG Hong.Developments in Real Time Three-Dimensional Transesophageal Echocardiography for Quantification of Valvular Heart Disease[J].Advances in Cardiovascular Diseases,2020,(5):1053.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.013]